First‐line PD‐1/PD‐L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4589
Abstract: Chemotherapy in combination with immune checkpoint inhibitor (ICI) or bevacizumab has demonstrated a superior effect for non‐squamous non‐small cell lung cancer (NS‐NSCLC). There are still few randomized controlled trials (RCTs) investigating the differences between ICI… read more here.
Keywords: plus chemotherapy; ici chemotherapy; first line; bev chemotherapy ... See more keywords
Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5757
Abstract: Pembrolizumab plus chemotherapy improved progression‐free survival (PFS) and overall survival (OS) compared with placebo plus chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple‐negative breast cancer with tumor programmed cell death ligand… read more here.
Keywords: plus chemotherapy; pembrolizumab plus; triple negative; negative breast ... See more keywords
The effect of liver metastases on clinical efficacy of first‐line programmed death‐1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM‐007 and meta‐analysis
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Medicine"
DOI: 10.1002/cam4.7203
Abstract: To explore the efficacy of serplulimab plus chemotherapy in esophageal squamous cell carcinoma (ESCC) patients with liver metastases. read more here.
Keywords: chemotherapy esophageal; esophageal squamous; analysis; plus chemotherapy ... See more keywords
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34687
Abstract: BACKGROUND EMPOWER-Lung 3, a randomized 2:1 phase 3 trial, showed clinically meaningful and statistically significant overall survival improvement with cemiplimab plus platinum-doublet chemotherapy versus placebo plus chemotherapy for first-line treatment of advanced non-small cell lung cancer. This study evaluated… read more here.
Keywords: plus chemotherapy; cemiplimab plus; lung; chemotherapy ... See more keywords
First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34296
Abstract: First‐line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)‐negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; read more here.
Keywords: nivolumab plus; plus chemotherapy; first line; chinese patients ... See more keywords
Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer
Sign Up to like & getrecommendations! Published in 2021 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-021-06572-4
Abstract: Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors plus chemotherapy have become the standard first line of treatment in patients with advanced non-small-cell lung cancer (NSCLC). However, few studies have explicitly focused on the impact… read more here.
Keywords: plus chemotherapy; inhibitors plus; treatment; weight loss ... See more keywords
Cellular immunotherapy plus chemotherapy ameliorates survival in gastric cancer patients: a meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-020-01750-6
Abstract: The efficacy of cellular immunotherapy plus chemotherapy in treatment of gastric cancer (GC) remains inconsistent even controversial. Hence, we performed a meta-analysis to better comprehend the clinical value of cellular immunotherapy plus chemotherapy for GC… read more here.
Keywords: plus chemotherapy; cellular immunotherapy; immunotherapy; immunotherapy plus ... See more keywords
Anlotinib plus chemotherapy as first-line treatment for advanced ovarian cancer: a prospective, single-arm, single-center, phase II clinical study
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic Oncology"
DOI: 10.1016/s0090-8258(21)00811-8
Abstract: Objectives: Anlotinib is an oral multi-kinase inhibitor that widely inhibits VEGFR, PDGFR, FGFR and c-kit. Previous researches have shown clinical antitumor activity of anlotinib in various cancers, including the gynecologic tumors. This investigator-initiated, single-arm, open-label,… read more here.
Keywords: plus chemotherapy; treatment; anlotinib plus; ovarian cancer ... See more keywords
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Sign Up to like & getrecommendations! Published in 2020 at "The Lancet"
DOI: 10.1016/s0140-6736(20)31953-x
Abstract: BACKGROUND Preferred neoadjuvant regimens for early-stage triple-negative breast cancer (TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy. IMpassion031 compared efficacy and safety of atezolizumab versus placebo combined with nab-paclitaxel followed by doxorubicin plus cyclophosphamide as neoadjuvant treatment… read more here.
Keywords: chemotherapy; chemotherapy group; placebo; stage ... See more keywords
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Sign Up to like & getrecommendations! Published in 2021 at "The Lancet"
DOI: 10.1016/s0140-6736(21)00797-2
Abstract: BACKGROUND First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median overall survival (OS) of less than 1 year. We aimed to evaluate first-line… read more here.
Keywords: chemotherapy alone; gastro oesophageal; gastric gastro; plus chemotherapy ... See more keywords
Adebrelimab versus serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China.
Sign Up to like & getrecommendations! Published in 2024 at "International journal of technology assessment in health care"
DOI: 10.1017/s0266462324000175
Abstract: Objective : We aimed to evaluate the cost-effectiveness of two first-line treatments newly approved 11 in the Chinese market for the treatment of extensive-stage small-cell lung cancer (ES-SCLC), 12 namely, adebrelimab plus chemotherapy (carboplatin+etoposide) and… read more here.
Keywords: plus chemotherapy; first line; treatment extensive; stage small ... See more keywords